News
MYMD
5.80
+1.75%
0.10
RUN, ARRY and SHLS are among pre market gainers
Pineapple Energy (PEGY) +75%. Atlas (<a href="https://seekingalph...
Seekingalpha · 4d ago
MyMD Pharmaceuticals Says Data Showing Co' MYMD-1 May Extend Life And Improve Health Published in the Journal of Gerontology: Biological Sciences
Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences Study of oral TNF-α inhibitor MYMD-1 demonstrates significant
Benzinga · 6d ago
Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders?
A look at the shareholders of MyMD Pharmaceuticals, Inc. ( NASDAQ:MYMD ) can tell us which group is most powerful...
Simply Wall St. · 07/29 13:19
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial Of MYMD-1 As A Therapy For Delaying Aging And Extending Healthy Lifespan
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and
Benzinga · 07/26 11:33
MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, July 26, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced furt...
Business Wire · 07/26 11:30
MyMD Pharmaceuticals to Advance Phase 2 Trial of Anti-Inflammatory Drug After Review Panel Confirmed No Safety Issues
MyMD Pharmaceuticals to Advance Phase 2 Trial of Anti-Inflammatory Drug After Review Panel Confirmed No Safety Issues
MT Newswires · 07/26 11:12
MyMD to collaborate with leading U.S. eye hospital Bascom on a pre-clinical study
MyMD Pharmaceuticals (NASDAQ:MYMD) on Tuesday <a href=...
Seekingalpha · 07/12 14:30
BRIEF-Mymd Pharmaceuticals To Collaborate With Bascom Palmer Eye Institute To Study Mymd-1 In Ophthalmic Conditions
BRIEF-Mymd Pharmaceuticals To Collaborate With Bascom Palmer Eye Institute To Study Mymd-1 In Ophthalmic Conditions
Reuters · 07/12 13:33
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
BALTIMORE, July 12, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that it has entered ...
Business Wire · 07/12 13:30
MyMD to Partner With Florida's Bascom Palmer Eye Institute Over Study of Potential Traumatic Optic Neuropathy Treatment
MT Newswires · 07/12 10:39
ORMP, SRAX and RVLP among mid-day movers
Gainers: Seritage Growth Properties (SRG) +72%. Ad...
Seekingalpha · 07/08 16:53
Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Oramed Pharmaceuticals' (NASDAQ:ORMP) Thursday announ...
Seekingalpha · 07/08 16:51
Dow Turns Positive After Better-Than-Expected Jobs Report
U.S. stocks turned higher midway through as investors digested the recent jobs report for the month of June.
Benzinga · 07/08 16:34
Why U.S. Stocks Are Trading Lower Despite Upbeat Nonfarm Payrolls Report
U.S. stocks traded lower this morning following the release of jobs report for the month of June.
Benzinga · 07/08 14:20
MyMD, Clovis top healthcare gainers; while RAPT, Veru lead losers' pack
Gainers: MyMD Pharmaceuticals (MYMD) +23%. Clovis Oncology (<...
Seekingalpha · 07/08 14:01
ONVO, FFIE and MYMD among pre market gainers
Seritage Growth Properties (SRG) +52%<a href="https://seekingalpha.com...
Seekingalpha · 07/08 12:28
BRIEF-Mymd Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial Of Mymd-1
reuters.com · 06/21 17:57
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in
Benzinga · 06/21 14:31
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, June 21, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in its fully-funded, multi-center Phase 2 c...
Business Wire · 06/21 14:30
MyMD Pharmaceuticals Says Patient Enrollment Under Way at All Sites in Phase 2 Study of Therapy to Delay Aging
MT Newswires · 06/21 12:37
More
Webull provides a variety of real-time MYMD stock news. You can receive the latest news about Mymd Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About MYMD
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (MAO) type B. Supera-CBD is also used in treating neuroinflammatory and neurodegenerative diseases.